<DOC>
	<DOC>NCT00729664</DOC>
	<brief_summary>Collection of survival data, evaluation of PDL-1 expression in tumors, and evaluation of PD-L1 receptor occupancy in peripheral blood has been added.</brief_summary>
	<brief_title>Multiple Ascending Dose (MDX1105-01)</brief_title>
	<detailed_description>This is an open label, multicenter, dose escalation and multidose study of MDX-11-5, a fully human monoclonal IgG4 antibody targeting the Programed Death-Ligand 1 (PD-L1). The study will consist of 3 periods: Screening (up to 28 days), Treatment (up to 16 six-week cycles), and Follow-up (up to 6 months).</detailed_description>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 The malignancies include relapsed/refractory renal cell carcinoma, nonsmall cell lung cancer, colorectal adenocarcinoma, malignant melanoma, advanced/metastatic epithelial ovarian cancer, gastric cancer, pancreatic cancer and breastcancer Must have measurable disease Prior therapy with an antiPD 1, antiPDL 1, or antiCytotoxic TLymphocyte Antigen 4 antibody (or any other agents that target Tcell costimulation)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>